Repligen (NASDAQ:RGEN) Stock Rating Upgraded by BidaskClub

Repligen (NASDAQ:RGEN) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Saturday, December 30th.

Several other research firms have also recently weighed in on RGEN. Stephens reiterated an “overweight” rating and issued a $50.00 price target on shares of Repligen in a report on Tuesday, September 26th. Jefferies Group restated a “hold” rating and set a $40.00 target price on shares of Repligen in a report on Thursday, September 14th. First Analysis upgraded shares of Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 target price for the company in a report on Monday, October 2nd. Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a report on Thursday, October 5th. Finally, CL King assumed coverage on shares of Repligen in a research report on Monday, November 13th. They set a “buy” rating and a $41.00 price target on the stock. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $44.38.

Shares of Repligen (NASDAQ RGEN) opened at $36.61 on Friday. The firm has a market cap of $1,590.00, a P/E ratio of 62.05, a P/E/G ratio of 2.05 and a beta of 1.04. Repligen has a 12 month low of $28.48 and a 12 month high of $46.81.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.04. The firm had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The business’s revenue for the quarter was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 earnings per share. equities analysts anticipate that Repligen will post 0.61 EPS for the current fiscal year.

In other news, VP Howard Benjamin sold 12,729 shares of the stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $35.34, for a total value of $449,842.86. Following the transaction, the vice president now directly owns 36,554 shares of the company’s stock, valued at $1,291,818.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in RGEN. Quantbot Technologies LP acquired a new position in shares of Repligen in the second quarter valued at about $120,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Repligen in the second quarter valued at about $123,000. Victory Capital Management Inc. grew its stake in shares of Repligen by 17.7% in the second quarter. Victory Capital Management Inc. now owns 4,001 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 601 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Repligen in the third quarter valued at about $180,000. Finally, Pinebridge Investments L.P. grew its stake in shares of Repligen by 1.7% in the second quarter. Pinebridge Investments L.P. now owns 4,491 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 76 shares in the last quarter. Institutional investors and hedge funds own 82.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/15/repligen-rgen-upgraded-to-buy-at-bidaskclub.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply